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Introduction: Hypertension affects more than a quarter of the global adult population.
Studies conducted worldwide suggest an overall small, yet useful, role of omega-3 PUFAs in
reducing blood pressure in hypertensive patients. However there is no substantial data in
this regard from population based in Middle East and Asia.
Objectives: To determine the effects of (omega-3) PUFA supplementation on the blood
pressure of hypertensive patient.
To identify if male and female hypertensive patients respond differently to PUFA.
To identify if response of hypertensive patients to PUFA varies with the duration of
hypertension and co-existence of diabetes/dyslipidemia.
Materials and methods: This observational study was conducted among hypertensive pa-
tients visiting OPD of the Gulf Medical College Hospital, Ajman, UAE, during the period Jan
eDec 2012. A total of 100 hypertensive patients on treatment with their antihypertensive
medications, 50 of whom were taking n-3 PUFA supplementation, were followed up for a
period of 3 months. Comparisons were drawn between the BP recordings at the time of
enrollment in the study and their follow up values 3 months after enrollment.
Results: There was a statistically significant reduction in both the systolic and diastolic
blood pressures after 3 months of PUFA therapy. The BP lowering effect of PUFA was more
in males. A statistically significant reduction in BP was noted in non-diabetic patients and
patients with long standing hypertension.
Conclusion: Findings of the study suggest that omega-3 PUFA dietary supplements augment
the benefits of pharmacotherapy in hypertension.
Copyright © 2014, Cardiological Society of India. All rights reserved.; fax: þ971 6 7431222.
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Hypertension is a global health problem. Its worldwide
prevalence in adults ages 25 years was about 40% in 2008.
Despite the modest drop in prevalence during the last two
decades, the number of individuals with uncontrolled hy-
pertension increased by about 400 million due to natural
population growth.1 Such prevalence is expected to increase
by atleast 24% and 80% in developed countries and devel-
oping countries respectively.2 In 2007 a study by Pathan et al,
stated that hypertension, even when severe, is commonly
underdiagnosed and undertreated in the UAE; thus preven-
tive strategies, better diagnosis and proper treatment
compliance should be emphasized to reduce incidence of
CVD in this population.3,4
Certain dietary interventions such as, reduced salt intake
and moderation of alcohol consumption in habitual alcohol
consumers, as well as, certain life style modifications such as
body weight optimization and well-planned exercise have
been shown to augment antihypertensivemedication therapy
in controlling hypertension. Diet that includes two to three
servings of oily fish per week has been often recommended by
several health organizations.5,6 Such recommendations stem
from the understanding that the intake of long chain omega-3
(n-3) fatty acids e namely eicosapentaenoic acid (EPA) and
docosahexaenoic acid (DHA) e which are highly available in
fatty fish and fish oils, possess cardiovascular protective ef-
fects that include but are not limited to blood pressure
reduction.7 Omega-3 fatty acids are a group of biologically
occurring Polyunsaturated Fatty Acids (PUFAs). DHA and EPA
are two long chain omega-3 fatty acids that function as pre-
cursors to eicosanoids e prostaglandins, thromboxanes, and
leukotrienesewhich are assumed to have anti-inflammatory,
antithrombotic, antiarrhythmic, and vasodilatory properties.
DHA and DPA are biosynthesized (in-vivo) from a short chain
fatty acid called alpha-linoleic acid (ALA). The rate of this
biosynthesis mechanism, however, is extremely low in
humans; which renders dietary supplementation the sole
source of DHA and EPA for humans.8,9
The purpose of our study is to verify whether there is an
effective role for omega-3 PUFA dietary supplements in the
treatment plans of hypertensive patients seen regularly at the
outpatient Department of Gulf Medical College Hospital
(GMCH) in Ajman, U.A.E and to examine if there exists unique
effects of omega-3 PUFAs on BP in a certain gender or ethnicity
of patients, and in patientswith a certain co-morbidity, within
our population of patients. It is worth noting that advising
hypertensive patients to consume omega-3 PUFA as dietary
supplements to augment their pharmacotherapy regimens is
a strategy that is utilized by some medical practitioners at
GMC. However, such dietary supplements are not covered by
most of our patients’ health insurance plans and thus patients
who opt to utilize those dietary supplements pay for them on
an out of pocket basis. The main driving force behind con-
ducting our study is to investigate whether we should
continue to advice our hypertensive patients at GMC to
regularly consume omega-3 PUFA dietary supplements. We
searched the ProQuest, Cochrane, PubMed, and Google
Scholar databases utilizing and meshing keywords such asPUFA, Omega-3 fatty acids, fish oil, dietary supplements,
blood pressure, and hypertension. We found out that many
small size randomized controlled trails (RCTs) were conduct-
ed over time in different parts of the world to objectively
investigate the relationship between consuming omega-3
PUFAs and blood pressure. In general, the results of such
studies did not have rigorous external validities so they could
not be extrapolated to various populations. Moreover, false
negative findings were likely in those randomized controlled
trials whenever sample sizes were not large enough or if blood
pressure measuring techniques were sub-optimal.10 We
found, as well, that Meta analyses and population based cross
sectional were consequently conducted to establish more
clinically meaningful relationships between omega-3 PUFAs’
consumption and blood pressure.
There are also however evidence in contrary to the cardio
protective effects of PUFA. Recent randomized controlled
studies, however, have made conclusions that the so talked
about benefits of PUFA are controversial and also suggest
possible harm with fish oil supplementation to patients
diagnosed with cardiovascular disease.11
Due to conflicting results in specific populations’ strata, we
could not establish strong recommendations regarding the
role of PUFAs dietary supplement preparations in the treat-
ment plans of hypertensive patients regularly seen at GMC,
nor could we determine whether such approach is more
useful to a specific gender, age-group, or patients with
particular co-morbidity such as Diabetes Mellitus. We decided
to conduct a prospective observational study that has an
intervention group and a comparison group to look at the ef-
fect of omega-3 PUFA regular intake on the level of hyper-
tension control in a group of hypertensive patients who are
recurrently seen at the outpatient department in GMC.2. Materials and methods
2.1. Study settings and population
This study was conducted among hypertensive patients
visiting OPD of Internal Medicine Department at the GMCH &
RC during the period June 2011eJan 2013. Patients diagnosed
with hypertension on treatment and prescribed PUFA were
included in the study. Patients using hormone replacement
therapy, and diagnosed with cardiac or c/c renal disease or
complications of hypertension were excluded from the
study. Based on evidence from available literature we ex-
pected a mean difference of 5 mm Hg and a SD of 8 and
hence the estimated sample size was calculated to be 50 in
each arm.
2.2. Study design and data collection
This observational study was approved by the Ethics Com-
mittee of the University and therefore been performed in
accordance with the ethical standards laid down in the 1964
Declaration of Helsinki. The study participants were briefed
about the purpose and objectives of the study before taking
consent from them. As a part of patient education, all hy-
pertensive patients attending the OPD of Internal medicine
Fig. 1 e Patient enrollment and follow up.
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health benefits of PUFA as a nutritional supplement and
prescribed 1 gm fish oil (Omacor tablets) daily. The re-
searchers screened all the hypertensive patients attending
the medicine OPD based on their inclusion and exclusion
criteria and enrolled them for the study. A pre-designed,
validated questionnaire was filled by one of the researchers
after interviewing the patient. The questionnaire recorded
the socioeconomic variables; details of hypertension-age of
onset, duration; history of dyslipidemia/diabetes and treat-
ment history e drugs, dosages and duration. Participants sat
quiet for atleast 5 min and three blood pressure readings
were taken using with a mercury manometer at 2 min in-
tervals and the average value was recorded in the question-
naire. After a follow up of 1 month the participants who
consumed PUFA supplement were categorized into PUFA
group and the others into control group. All the patients were
followed up for 2 more months. Enrollment of patients into
the study continued till the sample size of 50 was attained in
each group and each of the participants in both groups was
followed up for 2 more months after being allocated into the
groups (Fig. 1). Comparisons were drawn between the BP re-
cordings at the time of enrollment in the study and their
follow up values 3 months after enrollment.Table 1 e Gender, ethnicity and co-morbidity of comparison g
Variables Groups PUFA group (n ¼
Gender Male 22 (59.5)
Female 15 (40.5%)
Ethnicity Arab 35 (94.6%)
Asian 2 (5.4%)
Number of diabetic patients 10 (27%)
Number of patients on
lipid lowering drugs
33 (89%)2.3. Data analysis
Data was fed into Excel spreadsheet and transferred to PASW
19 version software for statistical analysis. Only subjects who
completed the study and had both baseline and final mea-
surements were included in the analysis. Chi-square test was
used to determine the association between the variables.
Paired and unpaired t-tests were used to compare the vari-
ables within the group and between the groups both prior to
and after the intervention. The significance level was
considered as p < 0.05.3. Results
3.1. Socio demographic characteristics
The participants of this study were of the mean age of
46.4 years and themean duration of hypertensionwas 5 years.
Majority of them were males (73%). Analysis of demographic
data revealed that 66% participants were of Arab origin while
the remainder of the populations was Asian.
Table 1 shows the baseline characteristics of the PUFA
group and control group. The two groups are found to beroup and PUFA group.
37) n (%) Comparison group (n ¼ 41) n (%) p
35 (85.4%) 0.01
6 (14.6%)
17 (41.5%) 0.001
24 (58.5%)
13 (31%) NS
23 (56%) 0.001
Table 2 e Blood pressure values at enrollment (mean ± SD).
Variables Groups PUFA group n ¼ 37 Comparison group n ¼ 41 p
Blood pressure of all participants Systolic BP 131.89 ± 18.64 138.76 ± 14.50 NS
Diastolic BP 85.27 ± 11.05 87.41 ± 10.61 NS
Blood pressure of diabetic patients Systolic BP 140.00 ± 25.386 141.54 ± 15.730 NS
Diastolic BP 87.50 ± 15.855 88.46 ± 12.810 NS
Blood pressure of patients on
lipid lowering drugs
Systolic BP 133.33 ± 19.15 137.09 ± 13.52 NS
Diastolic BP 86.21 ± 11.25 85.04 ± 9.89 NS
Table 3 e Comparison of BP values at enrollment and at 3 months of follow up (mean ± SD).
Variables Enrollment Follow up
PUFA group
(n ¼ 37)
Comparison group
(n ¼ 41)
p PUFA group
(n ¼ 37)
Comparison group
(n ¼ 41)
p
Systolic BP (mm Hg) 131.89 ± 18.68 138.76 ± 14.50 NS 122.89 ± 12.18 132.59 ± 13.44 <0.001
Diastolic BP (mm Hg) 85.27 ± 11.05 87.41 ± 10.61 NS 80.05 ± 6.33 84.78 ± 8.28 <0.01
Table 4 e Gender and changes in blood pressures
following PUFA therapy.
Gender Variables Enrollment Follow up p
Males
(n ¼ 22)
Systolic BP 132.27 ± 17.34 123.64 ± 13.99 <0.05
Diastolic BP 83.65 ± 10.02 80.45 ± 6.53 NS
Females
(n ¼ 15)
Systolic BP 131.33 ± 21.00 121.80 ± 9.26 NS
Diastolic BP 80.33 ± 11.10 79.47 ± 6.20 NS
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hypertension and their blood pressure values. There was a
significant difference in the gender distribution among both
the groups. The participants in the PUFA group were pre-
dominantly Arabs (94.6%) while Asians accounted for 58.5% of
the control group. Prevalence of diabetes was 27% in PUFA
group and 31% in control group. 89% of the patients in PUFA
were on lipid lowering drugs between the two groups. The BP
values of patients with diabetes and patients on lipid lowering
drugs were also comparable at the time of enrollment
(Table 2).
Table 3 shows the changes in blood pressure during the
study. Therewas a significant reduction in both the systolic and
diastolic blood pressures after 3months of PUFA therapy.While
thesystolicBPshowedameanreductionof 9.7mmHg (95%CIof
2.3e15.7), thediastolicpressure reducedbyameanof 4.7mmHg
(95% CI of 1.6e8.8) after PUFA therapy, when compared to the
patients on antihypertensivemedications alone.
As the groups were not comparable with regards to gender,
we used paired t-tests to analyze the response of different
genders to PUFA therapy, with the intervention group.
Following PUFA therapy the systolic blood pressure in males
showed a significant reduction of 9.63 (95% CI of 0.2e17.1).
Reduction was noted in the diastolic BP of males and both
systolic and diastolic blood pressure values of the female
participants as well, but this was not of statistical significance
(Table 4).
Hypertensive patients with diabetes showed reduction in
their blood pressure values on PUFA therapy (CI for Systolic BP
e 3.4e32.0, CI for diastolic BP e 3.0e15.6). However the
reduction was not statistically significant. The systolic BP of
non-diabetic patients showed a mean reduction of 7 mm Hg
(95% CI of 0.22e14.30) while the diastolic BP reduced by
5 mm Hg (95% CI of 0.8e8.8) (Table 5).
Significant blood pressures reduction of 13 mm Hg systolic
(95% CI of 1.5e24.5) and 6.75mmHg diastolic (95% CI 1.6e11.9)
was recorded, following PUFA therapy in participants with
hypertension of 5 years or more duration. Though consump-
tion of PUFA resulted in improvement of blood pressure
values in patients with hypertension of less than 5 years
duration, this was not statistically significant (Table 6).Consumption of PUFA along with statins resulted in a
significant decrease in both systolic and diastolic BP of pa-
tients when compared to patients on statin therapy alone.
Subgroup analysis could not be done to determine the dif-
ference in the effect of PUFA on the BP of patients who are on
antihypertensives and patients who are on statin therapy
along with antihypertensives due to insufficient sample size
(Table 7).4. Discussion
Dietary intake of 63 PUFA is known to reduce the incidence of
mortality and morbidity from cardiovascular diseases. The
reduction in the risk for arrhythmias, inhibition of growth of
atherosclerotic plaques, anti-inflammatory effects and
decrease in triglyceride levels caused by 63 PUFAseDHA and
EPA account for their advocated use in patients with cardio-
vascular diseases.11
The reduction caused by administration of PUFA in the
systolic and diastolic blood pressure of hypertensive patients
on treatment, as observed in our study is in accordance with
the Meta-analysis findings of Morris et al, that showed a sig-
nificant reduction in blood pressure of 3.4/2.0 mmHgwith the
consumption of omega-3 fatty acids.12 While a systematic
review of randomized controlled trials and cross over trials by
Campbell et al (2013) reported significant reductions in sys-
tolic and diastolic BP; 2.56 mm Hg (95% CI 0.58e4.53) and
1.47 mm Hg (95% CI 0.41e2.53) of hypertensive patients, they
did not find any significant reduction in BP values of normo-
tensive patients.13 Studies have also stated that the reduction
Table 5 e Diabetic status and changes in BP with PUFA therapy.
Disease groups Variables Enrollment Follow up p
Diabetic participants (n ¼ 10) Systolic BP 140.00 ± 25.39 125.70 ± 6.87 NS
Diastolic BP 87.50 ± 15.85 81.20 ± 6.05 NS
Non diabetic participants (n ¼ 27) Systolic BP 128.89 ± 15.02 121.85 ± 13.60 <0.05
Diastolic BP 84.44 ± 8.91 79.63 ± 6.50 <0.05
Table 6 e Duration of hypertension and changes in BP with PUFA therapy.
Duration of hypertension Variables Enrollment Follow up p
<5 years (n ¼ 17) Systolic BP 125.88 ± 10.04 121.59 ± 7.93 NS
Diastolic BP 82.94 ± 7.71 79.53 ± 5.81 NS
5 years (n ¼ 20) Systolic BP 137.00 ± 22.73 124.00 ± 15.01 <0.05
Diastolic BP 87.25 ± 13.13 80.50 ± 6.86 <0.05
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with PUFA than the improvement in diastolic blood pressure
values.11 A cross sectional study conducted by Ueshima et al
(2007) concluded that when compared to hypertensive in-
dividuals, consumption of foods containing PUFA had a
stronger inverse association with blood pressure values of
normotensives and in individuals who are not undergoing
dietary and/or medical interventions.10
The beneficial effects of PUFA on vascular function are
mediated by a wide range of biochemical and physiological
alterations. EPA and DHA are acted upon by cyclo-oxygenase
and lipo-oxygenase give rise to 3 series prostaglandins and 5
series leukotrienes. TxA3 is biologically inactive while PGI3 is
equipotent to PGI2 in causing vasodilatation and inhibiting
platelet aggregation hence the overall balance is shifted from
vasoconstriction to vasodilatation.14
Studies in both humans and animals have revealed that
long chain n-3 PUFAs inhibit the synthesis of TxA2 e a potent
vasoconstrictor.15 This effect may be produced by altering the
enzymes for its biosynthesis.16 Antagonism of TxA2 and PGH2
receptors is also another mechanism by which the blood
vessel is kept dilated by n-3 PUFA.17 Another endothelium
derived vasoconstrictor inhibited by EPA is Endothelin-1.
n-3 PUFAs increase endothelium-dependent relaxation by
enhancing the release of NO.18 The antioxidant action of n-3
PUFA is also known to reduce endothelial free radical damage
and thus restore the balance between VD and VC.19 Activation
of vascular Kþ channels and inhibition of Ca2þ channels
leads to hyperpolarisation and relaxation of vascular smooth
muscle was noted with treatment with PUFA.20
The metabolism of n-3 PUFAs by D5 and D6 desaturates is
known to be modified by genetic and epigenetic factors.
Genetic pleomorphism of genes for these enzymes result in
altered content of n-3 PUFA in membrane phospholipidsTable 7 e BP changes in patients on statins in PUFA and comp
Variable Enrollment
PUFA group
(n ¼ 33)
Comparison group
(n ¼ 23)
Systolic BP (mm Hg) 133.33 ± 19.15 137.09 ± 13.52
Diastolic BP (mm Hg) 86.21 ± 11.25 85.04 ± 9.89and hence their response in different individuals.21 This
could be postulated to be the reason for the less improve-
ment in BP values of females when compared to males in
our study. In contrast to our findings there has been data
suggesting no significant interaction between BP and
gender.10,11 Results of meta-regression analysis conducted
by Geleijnse (2002) suggest more significant reduction in
women than in men; however, no direct comparison be-
tween BP reductions in the two genders was made. In view
of these conflicting results more studies have to be con-
ducted to analyze the interactions between female hor-
mones and effect of PUFA.22
A rich source of dietary n-3 PUFA is known to reduce the
increased systolic blood pressure associated with long-term
diabetes in rats.23 Blood pressure also decreases in type 1
diabetic patients receiving supplements of n-3 PUFA.24 This is
consistent with the findings of our study where a reduction
was noted in the blood pressure values of hypertensive pa-
tients with diabetes. Obesity, malignancies and insulin resis-
tance are among the acquired causes of modifications in the
rate limiting enzymes of n-3 PUFA metabolism.7,25 This could
probably be the reason why the improvement seen in non-
diabetic hypertensives on PUFA therapy was significant when
compared to patients with diabetes co-existing with hyper-
tension in our study.
Endothelial dysfunction is present in various forms of
cardiovascular disease. Long standing hypertension com-
pounds endothelial dysfunction, decreasing responsiveness
to medications. In hypertension, reduction of BP per se does
not seem to restore endothelial function. Restoration of
endothelial function is seen following treatment of only few
underlying diseases.26 PUFAs by their mechanism of action
reduce the endothelial damage and hence maintain respon-
siveness to antihypertensive therapy.arison group (mean ± SD).
Follow up
p PUFA group
(n ¼ 33)
Comparison group
(n ¼ 23)
p
NS 123.24 ± 12.63 131.13 ± 14.25 <0.05
NS 79.76 ± 6.47 83.91 ± 7.22 <0.05
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reductase inhibitors (statins) has a relatively small but sta-
tistically significant effect on blood pressure. A meta-analysis
of the effect of statins on blood pressure in patients on
concomitant antihypertensive treatment revealed significant
reductions in both systolic and diastolic BP of patients taking
statins, in comparison with placebo group.27 In our study, it
was found that stains when consumed along with PUFA
supplements caused significant reduction in blood pressures
as compared to the group taking satins alone. This is in
accordance with the findings of Cicero AF (2010) who found
that PUFA supplementation for 1-year duration in hyper-
triglyceridemic patients on statin therapy with high normal
blood pressure resulted in a significant reduction in their
systolic BP, diastolic BP and pulse pressure. This hypotensive
action was found to be independent of its hypotriglyceridemic
effect.285. Limitations
Randomization was not performed, due to the fact that there
were financial; constraints in making the PUFA supplement
available to the patient. It was in such a scenariomore feasible
to observe patients who were in a position to pay for the same
by themselves. We were not able to control the effect of the
confounding factor of diet, due to lack of a validated ques-
tionnaire which is standardized for recording of dietary data
of the population based in UAE.6. Conclusion
From our observational study we found that supplementation
with n-3 PUFA (1 g/d) for 3 months causes significant reduc-
tion in BP of patients with hypertension on treatment. The
effect of PUFA was more pronounced in patients with long
standing hypertension. Co-existence of diabeteswas observed
to cause a decrease in response of patients to n-3 PUFA sup-
plements. Hence we like to conclude that in accordance with
data already available Omega-3 PUFA dietary supplements
have a beneficial effect as add-on modalities to augment
pharmacotherapy in hypertension. However the observation
that BP of females of Arab ethnicity shows a less response to
PUFA is a finding which needs to be investigated by genetic
studies.Conflicts of interest
All authors have none to declare.r e f e r e n c e s
1. WHO Global Health Data Repository; 2008. Retrived on Feb 26th,
2013 from: http://www.who.int/gho/ncd/risk_factors/blood_
pressure_prevalence_text/en/index.html.2. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK,
He J. Global burden of hypertension: analysis of worldwide
data. Lancet. 2005;365:217e223.
3. Tu K, Chen Z, Lipscombe L. Prevalence and incidence of
hypertension from 1995 to 2005: a population-based study.
Can Med Assoc J. 2008;178:1429e1435.
4. Pathan JY, Abdulle AM, Obineche EN. Hypertension in the United
Arab Emirates; 2007. Retrived on Feb 15 2013 from: http://
www.arabianbusiness.com/hypertension-in-united-arab-
emirates-148672.html.
5. Kris-Etherton PM, Harris WS, Appel LJ. Fish consumption, fish
oil, omega-3 fatty acids, and cardiovascular disease.
Circulation. 2002;106:2747e2757.
6. UK Scientific Advisory Committee on Nutrition. Advice on Fish
Consumption: Benefits and Risks. London, United Kingdom: The
Stationery Office; 2004.
7. Das UN. Essential fatty acidsda review. Curr Pharm Biotechnol.
2006;7:467e482.
8. Appel LJ, Brands MW, Daniels SR, Karanja N, Elmer PJ,
Sacks FM. Dietary approaches to prevent and treat
hypertension: a scientific statement from the American Heart
Association. Hypertension. 2006;47:296e308.
9. Covington Maggie B. Omega-3 fatty acids. Am Fam Physician.
2004;70:133e140.
10. Ueshima H, Stamler J, Elliott P, et al. Food omega-3 fatty acid
intake of individuals (total, linoleic acid, long-chain) and their
blood pressure: INTERMAP study. Hypertension.
2007;50:313e319.
11. Block Robert C, Pearson Thomas A. The cardio vascular
implications of Omega- 3 fatty acids. Folia Cardiol.
2006;13:557e569.
12. Leonarda De Rosa Maria. Can purified Omega-3
polyunsaturated fatty acids supplementation act blood
pressure levels in untreated normal-high blood pressure
subjects with hypertriglyceridemia? Pharmacol Pharm.
2012;3:234e239.
13. Morris MC, Sacks F, Rosner B. Does fish oil lower blood
pressure? A meta-analysis of controlled trials. Circulation.
1993;88:523e533.
14. Campbell F, Dickenson H, Critchley J, Ford G, Bradburn M. A
systematic review of fish-oil supplements for the prevention
and treatment of hypertension. Eur J Prev Cardiol.
2013;20:107e120.
15. Schmidt EB. Fish consumption, n23 fatty acids in cell
membranes, and heart rate variability in survivors of
myocardial infarction with left ventricular dysfunction. Am J
Cardiol. 1997;74:1670e1673.
16. Weber PC. Clinical studies on the effects of n23 fatty acids on
cells and eicosanoids in the cardiovascular system. J Intern
Med. 1989;225:61e68.
17. Abeywardena MY, McLennan PL, Charnock JS. Differential
effects of dietary fish oil on myocardial prostaglandin I and
thromboxane A production. Am J Physiol.
1992;260:H379eH385.
18. Abeywardena MY, Head RJ. In: Differential Antagonism by DHA
and EPA at the Thromboxane-A and Isoprostane Receptors in Rat
Aorta (abstr). 4th Congress of ISSFAL, June 4e9, Japan. 2000:68.
19. Abeywardena MY, Head RJ. Long chain n-3 polyunsaturated
fatty acids and blood vessel function. Cardiovasc Res.
2001;52:361e371.
20. Mori TA, Puddey IB, Burke V, et al. Effect of v-3 fatty acids on
oxidative stress in humans: GCMS measurement of urinary
F2- isoprostane excretion. Redox Rep. 2000;5:45e46.
21. Hirafuji M, Ebihara T, Kawahara F, Hamaue N, Endo T,
Minami M. Inhibition by docosahexaenoic acid of receptor-
mediated Ca(2þ) influx in rat vascular smooth muscle cells
stimulated with 5-hydroxytryptamine. Eur J Pharmacol.
2001;427:195e201.
i n d i a n h e a r t j o u r n a l 6 6 ( 2 0 1 4 ) 4 0 8e4 1 441422. Lattka E, Illig T, Koletzko B, Heinrich J. Genetic variantsof the
FADS1 FADS2 gene cluster as related to essential fatty acid
metabolism. Curr Opin Lipidol. 2010;21:64e69.
23. Geleijnse J, Giltay E, Grobbee D, Donders A, Kok F. Blood
pressure response to fish oil supplementation. J Hypertens.
2002;20:1493e1499.
24. Garman Joseph H, Mulroney Susan, Manigrasso Michaele,
Flynn Elizabeth, Maric Christine. AJP - Ren Physiol.
2009;296:F306eF316.
25. Jensen T, Stender S, Goldstein K, Hølmer G, Deckert T. Partial
normalization by dietary cod-liver oil of increased
microvascular albumin leakage in patients with insulin-dependent diabetes and albuminuria. N Engl J Med.
1989;321:1572e1577.
26. Reese C, Fradet V, Witte JS. u-3 Fatty acids,genetic variants in
COX-2 and prostate cancer. J Nutrigenetics Nutrigenomics.
2009;2:149e158,.
27. Endemann DH, Schiffrin LE. Endothelial dysfunction. JASN.
2004;15:1983e1992.
28. Strazzullo P, Kerry SM, Barbato A, Versiero M, D'Elia L,
Cappuccio FP. Do statins reduce blood pressure?: a meta-
analysis of randomized, controlled trials. Am J Hypertens.
2007;20:937e941.
